Benitec Biopharma Inc. cash flow statement
In fiscal 2024, Benitec Biopharma Inc.'s operations generated −$19.4m of cash; it spent $179,000 on capital projects, leaving free cash flow of −$19.6m.
Cash flow statement
| Fiscal year | 2019Jun 2019 | 2020Jun 2020 | 2021Jun 2021 | 2022Jun 2022 | 2023Jun 2023 | 2024Jun 2024 | LTMMar 2025 |
|---|---|---|---|---|---|---|---|
| Cash from operations | 5 | −8 | −13 | −16 | −18 | −19 | −19 |
| Depreciation and amortisation | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based pay | 1 | 0 | 1 | 1 | 0 | 1 | 12 |
| Capital spending | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Free cash flow | 4 | −8 | −13 | −16 | −18 | −20 | −19 |
| Free cash flow after stock pay | 4 | −8 | −14 | −17 | −18 | −20 | −30 |
| Shares issued | — | 2 | 26 | — | 18 | — | — |
| Quarter | 2024 Q3Mar 2024 | 2024 Q4Jun 2024 | 2025 Q1Sept 2024 | 2025 Q2Dec 2024 | 2025 Q3Mar 2025 | 2026 Q1Sept 2025 | 2026 Q2Dec 2025 | 2026 Q3Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | −6 | −3 | −5 | −8 | −3 | −3 | −4 | −4 |
| Depreciation and amortisation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based pay | 0 | 0 | 0 | 3 | 8 | 5 | 7 | 8 |
| Capital spending | — | 0 | — | — | 0 | — | — | 0 |
| Free cash flow | — | −3 | — | — | −3 | — | — | −4 |
| Free cash flow after stock pay | — | −4 | — | — | −11 | — | — | −12 |
| Shares issued | — | — | — | — | 30 | — | — | 0 |
More: Biotechnology stocks compared, Health Care sector, rankings of US companies